New Delhi, 16 September: An agreement has been reached between Russia’s Direct Investment Fund (RDIF) and Doctor Reddy’s Laboratories regarding the Corona virus vaccine Sputnik-V clinical trial and its distribution. Together, the two will provide 100 million vaccines in India.
However, the Russia has little capacity to produce such a large number of vaccines. This means that this vaccine will be produced in India, out of which 100 million vaccines will be given to India.
The agreement states that the vaccine will be made available in India after obtaining regulatory approval. The trial of this vaccine is currently underway and it is expected to be completed by the end of 2020.
RDIF CEO Kirill Dimitradev has said that Dr Reddy’s has a respectable position in Russia for the last 25 years and is a leading pharmaceutical company in India.
At the same time, India is one of the countries most affected by the corona virus. They feel that this drug will be safe and scientifically valid in dealing with Covid-19.
C Prasad, co-chairman and managing director of Dr Reddy’s Laboratories said the results of the vaccine’s face-one and face-two have proved promising. We will trial it in the third phase in India and prepare it according to the need of the Indian regulators.
